The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
A synthetic ten-membered oligopeptide comprising N-acetyl-3-(naphthalen-2-yl)-D-alanyl, 4-chloro-D-phenylalanyl, 3-(pyridin-3-yl)-D-alanyl, L-seryl, L-tyrosyl, N(5)-carbamoyl-D-ornithyl, L-leucyl, L-arginyl, L-prolyl, and D-alaninamide residues coupled in sequence. A gonadotrophin-releasing hormone (GnRH) antagonist, it is used for treatment of infertility and of hormone-sensitive cancers of the prostate and breast.
[cetrorelix co-treated with testosterone enanthate co-treated with Desogestrel] results in decreased expression of APOE mRNA; [cetrorelix co-treated with testosterone enanthate] results in decreased expression of APOE mRNA
[cetrorelix co-treated with testosterone enanthate co-treated with Desogestrel] results in decreased expression of CCN5 mRNA; [cetrorelix co-treated with testosterone enanthate] results in decreased expression of CCN5 mRNA
[cetrorelix co-treated with testosterone enanthate co-treated with Desogestrel] results in increased expression of CST9L mRNA; [cetrorelix co-treated with testosterone enanthate] results in increased expression of CST9L mRNA
[cetrorelix co-treated with testosterone enanthate co-treated with Desogestrel] results in decreased expression of CYP11A1 mRNA; [cetrorelix co-treated with testosterone enanthate] results in decreased expression of CYP11A1 mRNA
[cetrorelix co-treated with testosterone enanthate co-treated with Desogestrel] results in decreased expression of CYP17A1 mRNA; [cetrorelix co-treated with testosterone enanthate] results in decreased expression of CYP17A1 mRNA
[cetrorelix co-treated with testosterone enanthate co-treated with Desogestrel] results in increased expression of DDR1 mRNA; [cetrorelix co-treated with testosterone enanthate] results in increased expression of DDR1 mRNA
[cetrorelix co-treated with testosterone enanthate co-treated with Desogestrel] results in decreased expression of DHCR24 mRNA; [cetrorelix co-treated with testosterone enanthate] results in decreased expression of DHCR24 mRNA
[cetrorelix co-treated with testosterone enanthate co-treated with Desogestrel] results in decreased expression of DPEP3 mRNA; [cetrorelix co-treated with testosterone enanthate] results in decreased expression of DPEP3 mRNA
[cetrorelix co-treated with testosterone enanthate co-treated with Desogestrel] results in decreased expression of HMGCS2 mRNA; [cetrorelix co-treated with testosterone enanthate] results in decreased expression of HMGCS2 mRNA
[cetrorelix co-treated with testosterone enanthate co-treated with Desogestrel] results in decreased expression of INSL3 mRNA; [cetrorelix co-treated with testosterone enanthate] results in decreased expression of INSL3 mRNA
cetrorelix results in decreased expression of LHB protein cypermethrin inhibits the reaction [cetrorelix results in decreased secretion of LHB protein]
[cetrorelix co-treated with testosterone enanthate co-treated with Desogestrel] results in decreased expression of PAPSS2 mRNA; [cetrorelix co-treated with testosterone enanthate] results in decreased expression of PAPSS2 mRNA
[cetrorelix co-treated with testosterone enanthate co-treated with Desogestrel] results in decreased expression of PGRMC1 mRNA; [cetrorelix co-treated with testosterone enanthate] results in decreased expression of PGRMC1 mRNA
[cetrorelix co-treated with testosterone enanthate co-treated with Desogestrel] results in decreased expression of PROK1 mRNA; [cetrorelix co-treated with testosterone enanthate] results in decreased expression of PROK1 mRNA
[cetrorelix co-treated with testosterone enanthate co-treated with Desogestrel] results in decreased expression of RHOB mRNA; [cetrorelix co-treated with testosterone enanthate] results in decreased expression of RHOB mRNA
[cetrorelix co-treated with testosterone enanthate co-treated with Desogestrel] results in decreased expression of SYCP1 mRNA; [cetrorelix co-treated with testosterone enanthate] results in decreased expression of SYCP1 mRNA
[cetrorelix co-treated with testosterone enanthate co-treated with Desogestrel] results in decreased expression of TAF4B mRNA; [cetrorelix co-treated with testosterone enanthate] results in decreased expression of TAF4B mRNA
[cetrorelix co-treated with testosterone enanthate co-treated with Desogestrel] results in decreased expression of TEX19 mRNA; [cetrorelix co-treated with testosterone enanthate] results in decreased expression of TEX19 mRNA